<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844283</url>
  </required_header>
  <id_info>
    <org_study_id>2016-6-29</org_study_id>
    <nct_id>NCT02844283</nct_id>
  </id_info>
  <brief_title>Ad-HGF Treatment for Myocardial Infarction</brief_title>
  <official_title>Adenovirus Carrying Hepatocyte Growth Factor (Ad-HGF) Treatment for Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <brief_summary>
    <textblock>
      This will be the first clinical trial use Ad-HGF gene for the treatment of myocardial&#xD;
      infarction disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of cardiac left ventricular ejection fraction (LVEF, %)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>the difference of LVEF before and after treatment between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures (SF-36)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Participants will complete SF-36 to measure quality of life at baseline, 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity Status (DASI)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Participants will complete DASI questionnaires to measure activity status at baseline, 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of creatinine kinase (CK, U/L) within 24 hours post delivery.</measure>
    <time_frame>Baseline to 24 hours post delivery.</time_frame>
    <description>the difference of creatinine kinase (CK, U/L) before and after delivery within 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of troponin (μg/L) within 24 hours post delivery.</measure>
    <time_frame>Baseline to 24 hours post delivery.</time_frame>
    <description>the difference of troponin (μg/L) before and after delivery within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with evidence of any systemic embolization within 1 week post delivery.</measure>
    <time_frame>Baseline to 1 week post delivery.</time_frame>
    <description>number of participants with evidence of any systemic embolization during the hospitalization period post delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with clinically significant changes in ECG than before</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>number of participants with clinically significant changes in ECG than before</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with major acute cardiac events (cardiac death and myocardial infarction) during follow-up</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>number of participants with major acute cardiac events (cardiac death and myocardial infarction) during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with revascularization procedures during follow-up</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>number of participants with revascularization procedures during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ad-HGF</intervention_name>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-80 years of age&#xD;
&#xD;
               -  Clinical diagnosis of anterior ST-segment elevation myocardial infarction (STEMI)&#xD;
                  within the last 30 days, with any one of the following 12-lead&#xD;
                  electrocardiographic changes:&#xD;
&#xD;
               -  a) Greater than or equal to 2 mm ST-segment elevation) in 2 adjacent&#xD;
                  electrocardiographic precordial leads&#xD;
&#xD;
               -  b) A new left bundle branch block AND and an increase in cardiospecific enzymes&#xD;
                  &gt;3x CK, or increase in troponin compared to institution laboratory normal ranges&#xD;
&#xD;
               -  Successful PCI with stent implantation to infarct-related artery within the last&#xD;
                  30 days; defined as residual stenosis no greater than 30%, Thrombolysis In&#xD;
                  Myocardial Infarction (TIMI) flow of at least 2 and a reference diameter of at&#xD;
                  least &gt; 2mm&#xD;
&#xD;
               -  Is considered hemodynamically stable at time of enrollment and immediately prior&#xD;
                  to Ad-HGF delivery&#xD;
&#xD;
               -  Screening LVEF for the first 12 enrolled participants, must be no greater than&#xD;
                  40% by echocardiography (determined by Simpson's method) performed at least 2&#xD;
                  days after revascularization procedure. Subsequent participants enrolled in the&#xD;
                  trial, must have an LVEF no greater than 45%. (All screening echos done within&#xD;
                  the first 4 days post percutaneous coronary intervention (PCI) must be repeated&#xD;
                  either by echocardiography or MRI prior to Ad-HGF delivery to ensure that the&#xD;
                  variability does not exceed 10%)&#xD;
&#xD;
               -  In the case of a previous myocardial infarction, documented LVEF must be 50% or&#xD;
                  greater&#xD;
&#xD;
               -  Female participants must be surgically sterile, post-menopausal, have documented&#xD;
                  infertility, or are of child-bearing potential wih laboratory confirmation of&#xD;
                  non-pregnant state&#xD;
&#xD;
               -  Provided written informed consent and is willing to comply with study follow-up&#xD;
                  visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant unprotected left main disease (stenosis of 50% or greater)on diagnostic&#xD;
             angiography&#xD;
&#xD;
               -  An increase in LVEF by greater that 10% from initial LVEF evaluation for repeat&#xD;
                  assessments&#xD;
&#xD;
               -  The presence of significant coronary lesions, other than the index lesion of the&#xD;
                  infarction related artery&#xD;
&#xD;
               -  A history of significant ventricular arrhythmia not related to index STEMI&#xD;
&#xD;
               -  A history of cerebro-vascular accident or transient ischemic attack within 6&#xD;
                  months of enrollment&#xD;
&#xD;
               -  Inability to undergo apheresis procedure(i.e.: poor venous access, laboratory&#xD;
                  abnormalities&#xD;
&#xD;
               -  A history of uncorrected significant valvular heart disease&#xD;
&#xD;
               -  A history of left ventricular dysfunction prior to index STEMI&#xD;
&#xD;
               -  A history of human immunodeficiency virus (HIV)or hepatitis B or C infection&#xD;
&#xD;
               -  A history of malignancy within 5 years (Except for low-grade and fully resolved&#xD;
                  non-melanoma skin cancer)&#xD;
&#xD;
               -  A history of allergy to gentamycin or amphotericin&#xD;
&#xD;
               -  A history of non-compliance&#xD;
&#xD;
               -  Active inflammatory autoimmune disease requiring chronic immunosuppressive&#xD;
                  therapy&#xD;
&#xD;
               -  Creatinine clearance &lt;60 by Cockcroft-Gault Calculator&#xD;
&#xD;
               -  Confirmed pregnant or lactating&#xD;
&#xD;
               -  Is enrolled in a current investigational drug or device trial&#xD;
&#xD;
               -  Participant has received cell or gene therapy in past&#xD;
&#xD;
               -  The presence of any significant co-morbidities that, in the investigator's&#xD;
                  opinion, would preclude the participant from taking part in the trial&#xD;
&#xD;
               -  Inability to provide informed consent and comply with the follow-up visit&#xD;
                  schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HGF,myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

